Increased muscle force production and bone mineral density in actRIIB-Fc-treated mature rodents

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 68, Issue 10, 2013, Pages 1181-1192

  Chiu, Chi Sung ^a   Peekhaus, Norbert ^a   Weber, Hans ^a   Adamski, Sharon ^a   Murray, Edward M ^a   Zhang, Hai Zhuan ^a   Zhao, Jing Zhang ^a   Ernst, Robin ^a   Lineberger, Janet ^a   Huang, Lingyi ^a   Hampton, Richard ^a   Arnold, Beth Anne ^a   Vitelli, Salvatore ^a   Hamuro, Lora ^a   Wang, Wei Rong ^a   Wei, Nan ^a   Dillon, Greg M ^a   Miao, Jiangyong ^a   Alves, Stephen E ^a   Glantschnig, Helmut ^a   Wang, Fubao ^a   Wilkinson, Hilary A ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Activin receptor type IIB; Muscle; Myostatin; Sarcopenia

Indexed keywords

ACTIVIN RECEPTOR 2; ACTIVIN RECEPTOR TYPE II B; ACTIVIN RECEPTOR TYPE II-B; BIOLOGICAL MARKER; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; MSTN PROTEIN, MOUSE; MYOSTATIN; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE I N TERMINAL PEPTIDE; PROCOLLAGEN TYPE I N-TERMINAL PEPTIDE;

ACTIVIN RECEPTOR TYPE IIB; AGING; ANIMAL; ARTICLE; BLOOD; BONE DENSITY; C57BL MOUSE; CELL LINE; CELL STRAIN HEK293; DRUG EFFECT; HUMAN; MALE; METABOLISM; MOUSE; MUSCLE; MUSCLE CONTRACTION; MUSCLE STRENGTH; ORCHIECTOMY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SARCOPENIA; DRUG EFFECTS; HEK293 CELL LINE;

ACTIVIN RECEPTOR TYPE IIB; MUSCLE; MYOSTATIN; SARCOPENIA;

ACTIVIN RECEPTORS, TYPE II; AGING; ANIMALS; BIOLOGICAL MARKERS; BONE DENSITY; CELL LINE; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MALE; MICE; MICE, INBRED C57BL; MUSCLE CONTRACTION; MUSCLE STRENGTH; MYOSTATIN; ORCHIECTOMY; PEPTIDE FRAGMENTS; PROCOLLAGEN; RECOMBINANT FUSION PROTEINS; SARCOPENIA;

EID: 84885008251     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/glt030     Document Type: Article

References (69)

1. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997;387:83-90. (Pubitemid 27202654)
2. Zimmers TA, Davies MV, Koniaris LG, et al. Induction of cachexia in mice by systemically administered myostatin. Science. 2002;296:1486-1488. (Pubitemid 34553097)
3. Joulia-Ekaza D, Cabello G. Myostatin regulation of muscle development: molecular basis, natural mutations, physiopathological aspects. Exp Cell Res. 2006;312:2401-2414.
4. Mosher DS, Quignon P, Bustamante CD, et al. A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet. 2007;3:e79.
5. Langley B, Thomas M, Bishop A, Sharma M, Gilmour S, Kambadur R. Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J Biol Chem. 2002;277:49831-49840. (Pubitemid 36014431)
6. Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA. 2001;98:9306-9311. (Pubitemid 32743912)
7. Hacham M, White RM, Argov S, Segal S, Apte RN. Interleukin-6 and interleukin-10 are expressed in organs of normal young and old mice. Eur Cytokine Netw. 2004;15:37-46. (Pubitemid 38570176)
8. Rebbapragada A, Benchabane H, Wrana JL, Celeste AJ, Attisano L. Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol Cell Biol. 2003;23: 7230-7242. (Pubitemid 37211004)
9. Massagué J, Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J. 2000;19:1745-1754. (Pubitemid 30204386)
10. Lee SJ, Reed LA, Davies MV, et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci USA. 2005;102:18117-18122. (Pubitemid 41798511)
11. O hsawa Y, Hagiwara H, Nakatani M, et al. Muscular atrophy of caveolin- 3-deficient mice is rescued by myostatin inhibition. J Clin Invest. 2006;116:2924-2934. (Pubitemid 44684477)
12. Bogdanovich S, Krag TO, Barton ER, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature. 2002;420:418-421. (Pubitemid 35415652)
13. Akpan I, Goncalves MD, Dhir R, et al. The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity. Int J Obes (Lond). 2009;33:1265-1273.
14. Bradley L, Yaworsky PJ, Walsh FS. Myostatin as a therapeutic target for musculoskeletal disease. Cell Mol Life Sci. 2008;65:2119-2124.
15. Waters DL, Baumgartner RN, Garry PJ. Sarcopenia: current perspectives. J Nutr Health Aging. 2000;4:133-139.
16. Rantanen T, Guralnik JM, Foley D, et al. Midlife hand grip strength as a predictor of old age disability. JAMA. 1999;281:558-560. (Pubitemid 29081310)
17. Metter EJ, Talbot LA, Schrager M, Conwit R. Skeletal muscle strength as a predictor of all-cause mortality in healthy men. J Gerontol A Biol Sci Med Sci. 2002;57:B359-B365.
18. Roubenoff R. Sarcopenia: a major modifiable cause of frailty in the elderly. J Nutr Health Aging. 2000;4:140-142.
19. Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147:755-763. (Pubitemid 28183275)
20. Lynch GS. Update on emerging drugs for sarcopenia - age-related muscle wasting. Expert Opin Emerg Drugs. 2008;13:655-673.
21. Atkinson RA, Srinivas-Shankar U, Roberts SA, et al. Effects of testosterone on skeletal muscle architecture in intermediate-frail and frail elderly men. J Gerontol A Biol Sci Med Sci. 2010;65:1215-1219.
22. Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010;95:639-650.
23. Kovacheva EL, Hikim AP, Shen R, Sinha I, Sinha-Hikim I. Testosterone supplementation reverses sarcopenia in aging through regulation of myostatin, c-Jun NH2-terminal kinase, Notch, and Akt signaling pathways. Endocrinology. 2010;151:628-638.
24. Serra C, Tangherlini F, Rudy S, et al. Testosterone improves the regeneration of old and young mouse skeletal muscle. J Gerontol A Biol Sci Med Sci. 2013;68:17-26.
25. Fernández-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95:2560-2575.
26. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363:109-122.
27. An Z, Forrest G, Moore R, et al. IgG2m4, an engineered antibody isotype with reduced Fc function. MAbs. 2009;1:572-579.
28. Kim SK, Hebrok M, Li E, et al. Activin receptor patterning of foregut organogenesis. Genes Dev. 2000;14:1866-1871. (Pubitemid 30639520)
29. Weber H, Rauch A, Adamski S, et al. Automated rodent in situ muscle contraction assay and myofiber organization analysis in sarcopenia animal models. J Appl Physiol. 2012;112:2087-2098.
30. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715-725. (Pubitemid 47327396)
31. McPherron AC, Lee SJ. Suppression of body fat accumulation in myostatin-deficient mice. J Clin Invest. 2002;109:595-601. (Pubitemid 34204838)
32. Bialek P, Parkington J, Warner L, et al. Mice treated with a myostati/GDF-8 decoy receptor, ActRIIB-Fc, exhibit a tremendous increase in bone mass. Bone Abstracts. 2008;42:S46.
33. Kellum E, Starr H, Arounleut P, et al. Myostatin (GDF-8) deficiency increases fracture callus size, Sox-5 expression, and callus bone volume. Bone. 2009;44:17-23.
34. Lin SJ, Lerch TF, Cook RW, Jardetzky TS, Woodruff TK. The structural basis of TGF-beta, bone morphogenetic protein, and activin ligand binding. Reproduction. 2006;132:179-190. (Pubitemid 44269702)
35. Tsuchida K, Nakatani M, Uezumi A, Murakami T, Cui X. Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer. Endocr J. 2008;55:11-21. (Pubitemid 351520175)
36. Graham H, Peng C. Activin receptor-like kinases: structure, function and clinical implications. Endocr Metab Immune Disord Drug Targets. 2006;6:45-58. (Pubitemid 43796713)
37. Riches AC, Sharp JG, Thomas DB, Smith SV. Blood volume determination in the mouse. J Physiol (Lond). 1973;228:279-284.
38. Hennebry A, Berry C, Siriett V, et al. Myostatin regulates fiber-type composition of skeletal muscle by regulating MEF2 and MyoD gene expression. Am J Physiol Cell Physiol. 2009;296:C525-C534.
39. Hayashi S, Miyake M, Watanabe K, Aso H, Ohwada S, Yamaguchi T. Myostatin preferentially down-regulates the expression of fast 2x myosin heavy chain in cattle. Proc Jpn Acad Ser B Phys Biol Sci. 2008;84:354-362.
40. Girgenrath S, Song K, Whittemore LA. Loss of myostatin expression alters fiber-type distribution and expression of myosin heavy chain isoforms in slow- and fast-type skeletal muscle. Muscle Nerve. 2005;31:34-40. (Pubitemid 40053924)
41. Welle S, Bhatt K, Pinkert CA, Tawil R, Thornton CA. Muscle growth after postdevelopmental myostatin gene knockout. Am J Physiol Endocrinol Metab. 2007;292:E985-E991. (Pubitemid 46536498)
42. Gilson H, Schakman O, Combaret L, et al. Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy. Endocrinology. 2007;148:452-460. (Pubitemid 46021477)
43. Salehian B, Mahabadi V, Bilas J, Taylor WE, Ma K. The effect of glutamine on prevention of glucocorticoid-induced skeletal muscle atrophy is associated with myostatin suppression. Metabolism. 2006;55:1239-1247. (Pubitemid 44215944)
44. Cadena SM, Tomkinson KN, Monnell TE, et al. Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type. J Appl Physiol. 2010;109:635-642.
45. Bottinelli R, Reggiani C. Human skeletal muscle fibres: molecular and functional diversity. Prog Biophys Mol Biol. 2000;73:195-262.
46. Cairns SP, Robinson DM, Loiselle DS. Double-sigmoid model for fitting fatigue profiles in mouse fast- and slow-twitch muscle. Exp Physiol. 2008;93:851-862. (Pubitemid 351904249)
47. Pearsall RS, Canalis E, Cornwall-Brady M, et al. A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc Natl Acad Sci USA. 2008;105:7082-7087. (Pubitemid 351754533)
48. Matzuk MM, Kumar TR, Bradley A. Different phenotypes for mice deficient in either activins or activin receptor type II. Nature. 1995;374:356-360.
49. Lotinun S, Pearsall RS, Davies MV, et al. A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone. 2010;46:1082-1088.
50. Elkasrawy MN, Hamrick MW. Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. J Musculoskelet Neuronal Interact. 2010;10:56-63.
51. Gaddy-Kurten D, Coker JK, Abe E, Jilka RL, Manolagas SC. Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures. Endocrinology. 2002;143:74-83. (Pubitemid 34056405)
52. Sakai R, Fujita S, Horie T, et al. Activin increases bone mass and mechanical strength of lumbar vertebrae in aged ovariectomized rats. Bone. 2000;27:91-96. (Pubitemid 30365082)
53. Fuller K, Bayley KE, Chambers TJ. Activin A is an essential cofactor for osteoclast induction. Biochem Biophys Res Commun. 2000;268:2-7. (Pubitemid 30116600)
54. Ikenoue T, Jingushi S, Urabe K, Okazaki K, Iwamoto Y. Inhibitory effects of activin-A on osteoblast differentiation during cultures of fetal rat calvarial cells. J Cell Biochem. 1999;75:206-214. (Pubitemid 29463489)
55. Sugatani T, Alvarez UM, Hruska KA. Activin A stimulates IkappaBalpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. J Cell Biochem. 2003;90:59-67. (Pubitemid 37052309)
56. Funaba M, Ogawa K, Abe M. Expression and localization of activin receptors during endochondral bone development. Eur J Endocrinol. 2001;144:63-71. (Pubitemid 32126914)
57. Koncarevic A, Cornwall-Brady M, Pullen A, et al. A soluble activin receptor type IIb prevents the effects of androgen deprivation on body composition and bone health. Endocrinology. 2010;151: 4289-4300.
58. Nicholson EK, Stock SR, Hamrick MW, Ravosa MJ. Biomineralization and adaptive plasticity of the temporomandibular joint in myostatin knockout mice. Arch Oral Biol. 2006;51:37-49. (Pubitemid 41758529)
59. Hamrick MW, Pennington C, Byron CD. Bone architecture and disc degeneration in the lumbar spine of mice lacking GDF-8 (myostatin). J Orthop Res. 2003;21:1025-1032. (Pubitemid 37322384)
60. Morissette MR, Stricker JC, Rosenberg MA, et al. Effects of myostatin deletion in aging mice. Aging Cell. 2009;8:573-583.
61. Léger B, Derave W, De Bock K, Hespel P, Russell AP. Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation. Rejuvenation Res. 2008;11: 163-175B.
62. Siriett V, Salerno MS, Berry C, et al. Antagonism of myostatin enhances muscle regeneration during sarcopenia. Mol Ther. 2007;15:1463-1470. (Pubitemid 47099303)
63. LeBrasseur NK, Schelhorn TM, Bernardo BL, Cosgrove PG, Loria PM, Brown TA. Myostatin inhibition enhances the effects of exercise on performance and metabolic outcomes in aged mice. J Gerontol A Biol Sci Med Sci. 2009;64:940-948.
64. Murphy KT, Koopman R, Naim T, et al. Antibody-directed myostatin inhibition in 21-mo-old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function. FASEB J. 2010;24:4433-4442.
65. Sattler FR, Castaneda-Sceppa C, Binder EF, et al. Testosterone and growth hormone improve body composition and muscle performance in older men. J Clin Endocrinol Metab. 2009;94:1991-2001.
66. Perrini S, Laviola L, Carreira MC, Cignarelli A, Natalicchio A, Giorgino F. The GH/IGF1 axis and signaling pathways in the muscle and bone: mechanisms underlying age-related skeletal muscle wasting and osteoporosis. J Endocrinol. 2010;205:201-210.
67. Mendler L, Baka Z, Kovács-Simon A, Dux L. Androgens negatively regulate myostatin expression in an androgen-dependent skeletal muscle. Biochem Biophys Res Commun. 2007;361:237-242. (Pubitemid 47102291)
68. Borst SE, Conover CF. Orchiectomized Fischer 344 male rat models body composition in hypogonadal state. Life Sci. 2006;79:411-415. (Pubitemid 43817053)
69. Axell AM, MacLean HE, Plant DR, et al. Continuous testosterone administration prevents skeletal muscle atrophy and enhances resistance to fatigue in orchidectomized male mice. Am J Physiol Endocrinol Metab. 2006;291:E506-E516. (Pubitemid 44352256)